Insider Trading June 3, 2026 06:58 PM

Director's Stock Activity at Exelixis Amid Strong Financial and Clinical Updates

Analysis of a recent insider sale by an executive alongside positive quarterly earnings and key drug development collaborations.

By Sofia Navarro EXEL

A director at Exelixis, Inc., executed a significant stock sale in June 2026. This transaction occurred while the company's shares were trading near their 52-week high. The news was set against a backdrop of strong financial performance for Q1 2026 and major clinical developments, including a collaboration with Merck and positive subgroup analysis results from a Phase 3 trial.

Director's Stock Activity at Exelixis Amid Strong Financial and Clinical Updates
EXEL

Key Points

  • The recent sale of common stock by a director, Sue Gail Eckhardt, occurred in June 2026.
  • Exelixis reported robust financial results for the first quarter of 2026, exceeding expectations for both earnings and revenue. The company posted $0.87 per share in earnings and recorded $611 million in revenue, surpassing forecasts of $0.77 and $608.95 million, respectively.
  • The firm announced a clinical development collaboration with Merck for a Phase 3 trial focused on resected stage II/III colorectal cancer. Exelixis will sponsor the STELLAR-316 pivotal trial, utilizing Merck's subcutaneous anti-PD-1 therapy, KEYTRUDA QLEX.

Sue Gail Eckhardt, who serves as a director at Exelixis, Inc. (NASDAQ:EXEL), conducted a transaction involving the sale of company stock on June 1, 2026. Specifically, Ms. Eckhardt sold 9,812 shares of the firm's common stock, totaling $491,973 in value.

The details of the sale indicate that the individual shares were purchased at varying prices, ranging from $49.73 to $50.61 per share. The weighted average selling price for these units was determined to be $50.14. Notably, this transaction was structured and executed under a Rule 10b5-1 trading plan, a mechanism that Ms. Eckhardt adopted previously on November 11, 2025.


This reported insider activity takes place while Exelixis stock is currently trading near its 52-week high of $52.96, with the share price observed at $51.61. From a valuation standpoint, some analysis suggests that the stock may be undervalued at current levels, citing a Fair Value suggestion that implies potential upside for investors. The company maintains an

Risks

  • The timing of a significant director stock sale while the company is trading near its 52-week high may prompt questions regarding internal valuation perceptions.
  • While the analysis suggests an 'EXCELLENT' financial health score and a P/E ratio of 17.05, market sentiment remains subject to fluctuations based on future clinical trial outcomes or competitive developments.

More from Insider Trading

Maplebear Director Ravi Gupta Offloads $7.5 Million Stake Amid Steady Operational Metrics Jun 4, 2026 United Therapeutics Executive Mahon Liquidates $4.54 Million Stake Under Pre-Arranged Plan Jun 4, 2026 Globalstar Executive Disposes of Shares Amidst Valuation Questions and Acquisition Speculation Jun 4, 2026 Saba Capital Management Expands Stake in Highland Opportunities & Income Fund Jun 4, 2026 Oscar Health Executive Victoria Baltrus Liquidates Shares Under Pre-Arranged Plan Jun 4, 2026